首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 再生医学细胞疗法基因疗法

市场调查报告书

商品编码

1361767

全球细胞和基因治疗临床试验市场报告

Global Cell And Gene Therapy Clinical Trials Market Report

出版日期: 2023年10月01日 | 出版商:

Value Market Research | 英文 127 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球细胞和基因疗法临床试验市场的需求预计将从 2022 年的 97.2 亿美元达到 2030 年的近 529.3 亿美元，2023-2030 年研究期间复合年增长率为 20.72%。

细胞和基因疗法临床试验已迅速成为生物製药领域最具变革性的创新之一。 CGT 在超越其最初肿瘤学重点的治疗领域进行了测试，包括神经病学和眼科治疗。细胞和基因治疗临床试验掀起了生命科学产业的新一波创新浪潮。

市场动态：

CGT管道的增加是推动市场成长率的根本原因。此外，增加资金、研发投资以及成功的产品发布正在推动市场成长。此外，细胞和基因疗法临床试验市场在过去几年中出现了显着增长，製药公司合作为患者创造有效且易于使用的疗法。此外，细胞和基因治疗的临床研究与去年相比显着增加，因为研究人员现在将重点转向基因治疗，因为它具有治疗癌症或罕见疾病的潜力。这种转变预计将推动市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球细胞和基因治疗临床试验市场的各个部分进行了包容性评估。细胞和基因治疗临床试验产业的成长和趋势为这项研究提供了整体方法。

区域分析：

本节涵盖区域展望，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的细胞和基因治疗临床试验市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。细胞和基因治疗临床试验市场的主要参与者包括 IQVIA、ICON Plc、Laboratory Corporation of America Holdings、Charles River Laboratories International, Inc.、PAREXEL International Corp.、Syneos Health、Medpace, Holdings, Inc.、PPD Inc.。、Novotech、Veristat LLC。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概述、历史和预测销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概述、历史和预测销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概述、历史和预测销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概述、历史和预测销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概述、历史和预测销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：细胞与基因疗法临床试验公司的竞争格局

细胞与基因治疗临床试验市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
IQVIA

公司简介
公司收入
产品
最近的发展

ICON Plc

公司简介
公司收入
产品
最近的发展

Laboratory Corporation of America Holdings

公司简介
公司收入
产品
最近的发展

Charles River Laboratories International Inc.

公司简介
公司收入
产品
最近的发展

PAREXEL International Corp.

公司简介
公司收入
产品
最近的发展

Syneos Health

公司简介
公司收入
产品
最近的发展

Medpace

公司简介
公司收入
产品
最近的发展

Holdings Inc.

公司简介
公司收入
产品
最近的发展

PPD Inc.

公司简介
公司收入
产品
最近的发展

Novotech

公司简介
公司收入
产品
最近的发展

Veristat LLC

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR11218697

The global demand for Cell And Gene Therapy Clinical Trials Market is presumed to reach the market size of nearly USD 52.93 BN by 2030 from USD 9.72 BN in 2022 with a CAGR of 20.72% under the study period 2023 - 2030.

Cell and gene therapies clinical trials have quickly emerged as one of the most transformative innovations in biopharmaceuticals. CGTs are tested in therapeutic areas beyond their initial oncology focus, including neurology and ophthalmology treatment. Cell and gene therapy clinical trials present a new wave of innovation in the life sciences industry.

MARKET DYNAMICS:

The rise in the CGT pipeline is the root cause fuelling the market growth rate. Also, increasing funding, investments in research and development, and successful product launches are boosting the market growth. Moreover, the market of cell and gene therapy clinical trials has witnessed significant growth over the past few years, with pharma firms partnering to create effective and accessible therapies for patients. Furthermore, cell and gene therapy clinical studies increased significantly compared to last year, as researchers are now shifting their focus to gene therapy because of its potential to treat cancer or rare diseases. This shift is expected to fuel the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell and gene therapy clinical trials. The growth and trends of cell and gene therapy clinical trials industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cell and gene therapy clinical trials market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Phase

Phase I
Phase II
Phase III
Phase IV

By Indication

Oncology
Cardiology
CNS
Musculoskeletal
Infectious Diseases
Dermatology
Endocrine, Metabolic, Genetic
Immunology & Inflammation
Ophthalmology
Hematology
Gastroenterology
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cell And Gene Therapy Clinical Trials market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cell and gene therapy clinical trials market include IQVIA, ICON Plc, Laboratory Corporation of America Holdings, Charles River Laboratories International, Inc., PAREXEL International Corp., Syneos Health, Medpace, Holdings, Inc., PPD Inc., Novotech, Veristat LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CELL AND GENE THERAPY CLINICAL TRIALS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Phase
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY PHASE

6.1 Overview by Phase
6.2 Historical and Forecast Data
6.3 Analysis by Phase
6.4 Phase I Historic and Forecast Sales by Regions
6.5 Phase II Historic and Forecast Sales by Regions
6.6 Phase III Historic and Forecast Sales by Regions
6.7 Phase IV Historic and Forecast Sales by Regions

7 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Oncology Historic and Forecast Sales by Regions
7.5 Cardiology Historic and Forecast Sales by Regions
7.6 CNS Historic and Forecast Sales by Regions
7.7 Musculoskeletal Historic and Forecast Sales by Regions
7.8 Infectious Diseases Historic and Forecast Sales by Regions
7.9 Dermatology Historic and Forecast Sales by Regions
7.10. Endocrine, Metabolic, Genetic Historic and Forecast Sales by Regions
7.11 Immunology & Inflammation Historic and Forecast Sales by Regions
7.12 Ophthalmology Historic and Forecast Sales by Regions
7.13 Hematology Historic and Forecast Sales by Regions
7.14 Gastroenterology Historic and Forecast Sales by Regions
7.15 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE CELL AND GENE THERAPY CLINICAL TRIALS COMPANIES

9.1. Cell And Gene Therapy Clinical Trials Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF CELL AND GENE THERAPY CLINICAL TRIALS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. IQVIA
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. ICON Plc
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Laboratory Corporation of America Holdings
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Charles River Laboratories International Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. PAREXEL International Corp.
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Syneos Health
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Medpace
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Holdings Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. PPD Inc.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Novotech
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Veristat LLC
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments